Literature DB >> 23372287

A randomized controlled trial comparing two different antibiotic regimens for prophylaxis at cesarean section.

Gourisankar Kamilya1, Subrata Lall Seal, Joydev Mukherji, Himangsu Roy, Subir Kumar Bhattacharyya, Avijit Hazra.   

Abstract

OBJECTIVES: To compare the efficacy of intravenous single dose, less costly cefotaxime and more expensive amoxycillin-clavulanic acid combination for prophylaxis at cesarean section.
METHOD: A double blind randomized controlled trial was undertaken on 760 subjects with two parallel treatment groups. Data were analyzed using Graphpad Instat 3 McIntosh software by Student's t test, Mann-Whitney U test, the Chi-squared test or fisher's exact test.
RESULTS: Comparatively narrow spectrum low cost cefotaxime is as effective as more expensive commonly used amoxicillin-clavulanic acid with no significant difference of infectious morbidity and hospital stay (p = 0.27 and 0.11 in elective and emergency cases respectively).
CONCLUSION: Less costly cefotaxime should be preferred compared to more costly amoxicillin-clavulanic acid combination for prophylaxis at cesarean section.

Entities:  

Keywords:  Antibiotic; Cesarean section; Prophylaxis

Year:  2012        PMID: 23372287      PMCID: PMC3366565          DOI: 10.1007/s13224-012-0148-6

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  10 in total

1.  The routine use of cefazolin in cesarean section.

Authors:  A A Rouzi; F Khalifa; H Ba'aqeel; H S Al-Hamdan; N Bondagji
Journal:  Int J Gynaecol Obstet       Date:  2000-05       Impact factor: 3.561

2.  Antibiotic prophylaxis at caesarean section.

Authors:  Stephen Mark Wild
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

Review 3.  Antibiotic prophylaxis regimens and drugs for cesarean section.

Authors:  L Hopkins; F Smaill
Journal:  Cochrane Database Syst Rev       Date:  2000

4.  Prophylactic use of antibiotics for nonlaboring patients undergoing cesarean delivery with intact membranes: a meta-analysis.

Authors:  D Chelmow; M S Ruehli; E Huang
Journal:  Am J Obstet Gynecol       Date:  2001-03       Impact factor: 8.661

5.  Timing of prophylactic antibiotic administration in the uninfected laboring gravida: a randomized clinical trial.

Authors:  Brad D Thigpen; W Ashley Hood; Suneet Chauhan; Laura Bufkin; James Bofill; Everett Magann; John C Morrison
Journal:  Am J Obstet Gynecol       Date:  2005-06       Impact factor: 8.661

6.  Impact of antibiotic prophylaxis on wound infection after cesarean section in a situation of expected higher risk.

Authors:  M W Mah; A M Pyper; G A Oni; Z A Memish
Journal:  Am J Infect Control       Date:  2001-04       Impact factor: 2.918

7.  Single or triple dose piperacillin prophylaxis in elective cesarean section.

Authors:  S Shah; Y Mazher; I S John
Journal:  Int J Gynaecol Obstet       Date:  1998-07       Impact factor: 3.561

8.  Comparison of ceftriaxone versus triple drug regimen in the prevention of cesarean section infectious morbidities.

Authors:  L O Alekwe; O Kuti; E O Orji; S O Ogunniyi
Journal:  J Matern Fetal Neonatal Med       Date:  2008-09

Review 9.  Antibiotic prophylaxis for cesarean section.

Authors:  F Smaill; G J Hofmeyr
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Incidence of postpartum endomyometritis following single-dose antibiotic prophylaxis with either ampicillin/sulbactam, cefazolin, or cefotetan in high-risk cesarean section patients.

Authors:  N Noyes; A S Berkeley; K Freedman; W Ledger
Journal:  Infect Dis Obstet Gynecol       Date:  1998
  10 in total
  2 in total

Review 1.  Different classes of antibiotics given to women routinely for preventing infection at caesarean section.

Authors:  Gillian M I Gyte; Lixia Dou; Juan C Vazquez
Journal:  Cochrane Database Syst Rev       Date:  2014-11-17

2.  Different classes of antibiotics given to women routinely for preventing infection at caesarean section.

Authors:  Myfanwy J Williams; Carolina Carvalho Ribeiro do Valle; Gillian Ml Gyte
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.